New drug cocktail aims to fight Hard-to-Treat sarcomas
NCT ID NCT05941325
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests a combination of two drugs—fruquintinib (which blocks blood vessel growth) and envafolimab (an immunotherapy)—in 20 people with advanced or unresectable bone and soft tissue sarcoma. The goal is to see if the combo can slow tumor growth or shrink tumors. The study is currently suspended, and results are not yet available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- fruquintinib (a drug that blocks blood vessel growth) and envafolimab (an immunotherapy drug)
- What this could lead to
- If it works, this combination could offer a new treatment option for people with advanced sarcoma that has not responded to other therapies.
- What could go wrong
- This is a small, early-phase trial (20 people) that is currently suspended, so results are uncertain. The drugs may cause side effects like high blood pressure or immune-related reactions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED OR UNRESECTABLE LOCALLY ADVANCED BONE AND SOFT TISSUE SARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shanghai No.6 People Hospital
Shanghai, Shanghai Municipality, China